Is Paxlovid a Strong CYP3A Inhibitor? Unpacking the Drug-Drug Interaction Risks
•
4 min read
The US Food and Drug Administration (FDA) has explicitly warned that Paxlovid, a leading COVID-19 treatment, includes ritonavir, a **strong CYP3A inhibitor**. This potent inhibition can lead to significant and potentially dangerous drug-drug interactions, raising plasma concentrations of other medications and resulting in severe or life-threatening adverse events.
